Sleep hyperkinetic (hypermotor) epilepsy …

Isaac Molinero MD

Epilepsy & Seizures

Updated 07.19.2024
Released 08.04.2009
Expires For CME 07.19.2027

Sleep hyperkinetic (hypermotor) epilepsy

Author: Isaac Molinero MD

See Contributor Disclosures

Editor: Solomon L Moshé MD

Sleep hyperkinetic (hypermotor) epilepsy

In This Article

Quick Link

Introduction

Overview

Based on the expert consensus of the International League Against Epilepsy Nosology and Definitions Taskforce (2017–2021), “autosomal dominant nocturnal frontal lobe epilepsy" has been renamed “sleep-related hypermotor (hyperkinetic) epilepsy” to reflect the current understanding that this syndrome includes characteristic motor seizure types (hyperkinetic seizures and/or motor seizures with tonic/dystonic features), predominantly from sleep, and that these can be of extra frontal onset. A wider range of etiologies is now associated with this syndrome, derived from advances in imaging, genetic, and EEG investigations.

With the discovery of a mutation in the nicotinic acetylcholine receptor alpha4 subunit gene in one family, sleep-related hypermotor epilepsy became the first human epilepsy in which a gene was identified. Mutations have been found in genes encoding the nicotinic acetylcholine receptor alpha4, beta2, and alpha2 subunits. A sodium-gated potassium channel gene, KCNT1, has also been identified in severe ADNFLE, associated with intellectual disability and psychiatric features. Missense mutations in both the promoter and coding regions of CRH, the gene encoding corticotropin-releasing hormone, have been identified in sleep-related hypermotor epilepsy families. Mutations in mTOR regulator genes, DEPDC5, NPRL2, and NPRL3, have been identified as causes of familial focal epilepsy with variable foci, of which a subgroup of families has ADSHE.

Key points

	• The etiology of sleep-related hypermotor epilepsy may be genetic, genetic–structural, or acquired.
	• Seizures may be misdiagnosed as parasomnias, nightmares, or nonepileptic seizures.
	• More severe cases may have intellectual disability, regression, and psychiatric features.
	• Familial sleep-related hypermotor epilepsy is usually inherited in an autosomal dominant fashion (autosomal dominant sleep-related hypermotor epilepsy [ADSHE]), with a penetrance of approximately 70%.
	• ADSHE is associated with mutations of acetylcholine nicotinic receptor genes CHRNA4, CHRNB2, and CHRNA2, the sodium-gated potassium channel gene KCNT1, corticotropin-releasing hormone gene (CRH), and the genes DEPDC5, NPRL2, and NPRL3 involved in mTOR regulation.
	• Some ADSHE families may be regarded as a subset of familial focal epilepsy with variable foci due to mutations in the GATOR1 genes, DEPDC5, NPRL2, and NPRL3.

Historical note and terminology

In 1981, five patients with frequent sleep-related events were reported by Lugaresi and Cirignotta (32). These individuals had frequent stereotyped events, occurring almost every night, characterized by tonic and dystonic posturing and coarse, violent movements. The episodes all arose from stage 2 sleep, were not associated with epileptiform abnormalities on EEG, and were responsive to carbamazepine. Lugaresi and Cirignotta named this condition hypnogenic paroxysmal dystonia and suggested three possible underlying mechanisms. They suggested that the movements could be a form of sleep terror (ie, a benign parasomnia), a form of paroxysmal dystonia triggered by arousal from sleep (ie, a movement disorder), or a form of epilepsy arising from deep or mesial structures.

Over the next decade, further reports of this condition appeared in the literature. Although evidence for an epileptic basis was seen in some cases, in others the association with the subsequent development of Huntington disease (33) or concurrent reflex dystonia (28) suggested that nocturnal paroxysmal dystonia was in fact a movement disorder. It was hypothesized, therefore, that the condition was heterogeneous and included paroxysmal disorders with different underlying etiologies. In general, brief attacks (which tended to be more responsive to antiepileptic agents) were held to be epileptic in origin, whereas the rarer longer attacks (many of which did not respond to antiepileptic drugs) were thought to represent extrapyramidal disturbances (74). The condition became widely known as nocturnal paroxysmal dystonia.

At this time, reports were also emerging of patients with multiple, very brief, arousals from NREM sleep. These arousals caused significant sleep fragmentation and daytime somnolence, and in some cases appeared to have an epileptic basis (50; 41). In addition, the phenomenon of episodic nocturnal wanderings was described (49; 35), characterized by longer episodes of vocalization, complex and sometimes violent automatisms, and ambulation.

The nature of these episodes, particularly nocturnal paroxysmal dystonia, was widely debated (27; 08), but as more work was performed on the semiology of frontal lobe epilepsy, the similarities between nocturnal paroxysmal dystonia and frontal lobe seizures became apparent. Both conditions presented with prominent tonic and dystonic features or bizarre automatisms, were often associated with preservation of consciousness, and frequently had no associated ictal EEG changes (59; 68; 79; 77; 43). The tendency of frontal lobe seizures to occur in sleep was also recognized. These striking similarities, combined with the presence of definite epileptiform discharges in a number of nocturnal paroxysmal dystonia patients, resulted in the view of some that most (if not all) nocturnal paroxysmal dystonia cases were epileptic in origin (73; 36), and the term “nocturnal frontal lobe epilepsy” (NFLE) was coined. In 2016, the results of a consensus conference were published, proposing the name be changed to “sleep-related hypermotor epilepsy,” emphasizing the importance of sleep triggering seizure onset rather than time of day and the evidence that seizures do not always arise in the frontal lobe (72).

In 1994, Scheffer and colleagues reported a group of families from Australia, Canada, and the United Kingdom in whom sleep-related hypermotor epilepsy was inherited in an autosomal dominant fashion, thus, describing autosomal dominant sleep-related hypermotor epilepsy (ADSHE) (64). The largest family in this study was mapped with linkage analysis to chromosome 20q (53), and a genetic mutation was subsequently identified in a nicotinic acetylcholine subunit gene (70), making ADSHE the first form of human epilepsy for which the fundamental genetic basis had been established. A wider range of etiologies are now associated with this syndrome, derived from advances in imaging, genetic, and EEG investigations.

Clinical manifestations

Presentation and course

Seizure onset usually occurs in the second decade of life with a mean age of onset of 11 to 14 years, but with a very wide range of onset from 2 months to 64 years. The only mandatory core diagnostic criteria for sleep-related hypermotor (hyperkinetic) epilepsy is brief focal motor seizures with hyperkinetic or asymmetric tonic/dystonic features occurring predominantly from sleep. A mean of 20 seizures per month is reported, with 1 to 20 seizures occurring per night. Most individuals have no identifiable trigger for their seizures. Approximately one third of patients have occasional daytime seizures, and for a similar proportion, focal seizures evolve to bilateral tonic-clonic seizures, both usually occurring during periods of poor seizure control. A significant number of individuals with sleep-related hypermotor epilepsy also report a personal or family history of events that are clinically consistent with benign parasomnias such as sleepwalking and sleep terrors. Some patients with sleep-related hypermotor epilepsy may complain only of sleep disturbance, and others may be unaware of their events, with the seizures only being reported by relatives. In some cases of “sporadic sleep-related hypermotor epilepsy,” a family history of nocturnal events may be suggestive of a diagnosis of ADSHE if family members are also experiencing focal seizures that may not have been recognized.

Exclusionary criteria for the diagnosis of sleep-related hypermotor epilepsy include seizures only during wakefulness, generalized onset seizures, and age of onset younger than 2 months or over 64 years of age.

Focal motor seizures with vigorous hyperkinetic or asymmetric tonic/dystonic features are seen, usually with autonomic signs (tachycardia, tachypnea, irregular respiratory rhythm), vocalization, and negative emotional expression, such as fear. There may be head and eye deviation. Hyperkinetic movements involve proximal limb or axial muscles, producing irregular large-amplitude movements, such as pedaling, pelvic thrusting, jumping, thrashing, or rocking movements. Focal motor seizures may be clinically subtle (previously termed "paroxysmal arousals") or may have longer duration and greater complexity (such as "epileptic wandering"). Patients may describe a focal aware sensory or cognitive seizure before the motor features commence. Focal to bilateral tonic–clonic seizures can occur. Although occurrence of seizures from sleep is characteristic of this syndrome, seizures from the awake state occur in 27% to 45% of patients at some time in their life.

Neurologic examination is usually normal. Neuroimaging studies may be normal or show a focal cortical dysplasia or acquired structural abnormality. The interictal EEG tends to show a normal background although focal (usually frontal) epileptiform abnormalities can be seen. When patients with sleep-related hypermotor epilepsy are studied using video EEG monitoring, by far the most common seizure type recorded is the paroxysmal arousal; paroxysmal nocturnal dystonia is seen less frequently, with episodic nocturnal wanderings recorded infrequently. Most patients have at least two of these seizure types identifiable on monitoring, and autonomic features such as tachycardia and irregular respiration are also prominent.

Prognosis and complications

The prognosis of sleep-related hypermotor epilepsy is predominantly related to the underlying etiology. Most patients have normal intellect and normal imaging and respond to first-line antiseizure medications. However, intellectual disability and behavior disorders have been reported in sleep-related hypermotor epilepsy, especially in the familial form related to mutations in KCNT1. Patients with intellectual disability, neurologic or imaging abnormality, or seizures in wakefulness are less likely to achieve sustained seizure remission. Epilepsy surgery may be effective in selected etiologies. The best surgical outcome is seen when the etiology is a well-defined structural pathology, especially focal cortical dysplasia type IIb.

However, it is increasingly recognized that in some cases, sleep-related hypermotor epilepsy may have a more severe presentation. Some individuals have highly refractory epilepsy throughout their lives, with periods of status epilepticus. They may also have significant psychiatric and cognitive morbidity (34; 16). Moreover, evidence is accumulating that even in relatively mildly affected individuals, neuropsychological abnormalities of frontal lobe function may be identified on formal testing (56; 81). In a cohort of 60 individuals with sleep-related hypermotor epilepsy, 15% had intellectual disability or cognitive deterioration and nearly half had deficits in at least one test of cognitive function (30).

As discussed earlier, the clinical features of sleep-related hypermotor epilepsy in most families with different mutations are indistinguishable. There is some evidence, however, to suggest that phenotypic features such as severity of epilepsy, and cognitive and psychiatric morbidity, may be influenced by the specific underlying genetic mutation. Steinlein and colleagues analyzed the clinical features of 150 affected individuals from 19 families in 12 countries and found that certain nAChR mutations appeared to confer a higher risk for mental retardation, schizophrenia-like symptoms, and marked cognitive deficits (69). For example, only 2 of 67 identified individuals with the CHRNA4-S248F mutation had major psychiatric or neurologic features, and only minor neuropsychological deficits were found on formal testing. In contrast, 11 of the 19 known individuals with the CHRNA4-S252L mutation had intellectual capacities in the low normal or moderately intellectually disabled range, and most individuals developed epilepsy at a younger age (6 months to 2 years). However, the small numbers involved in such studies, along with multiple other potential confounding factors, make definitive conclusions difficult.

Clinical vignette

A 33-year-old man presented with nocturnal attacks from the age of 10 years. The events were characterized by waking from sleep with a sensation of his breath “locking in his throat,” feeling unable to breathe. The episodes would usually happen soon after he had fallen asleep (within 30 minutes to an hour) and would often occur 5 to 10 times in close succession on the same night over a few hours. He felt he had partial or full recollection of all the events. He remembered sitting forward during the attacks and sometimes shouting “help.” His mother described how he would suddenly sit forward, with a distressed facial expression and apparently hyperventilating. His legs would kick and his arms would be held stiffly out to his sides, and he would shout. The attacks usually lasted 30 seconds to a minute, but occasionally they would last up to 2 minutes. They occurred exclusively from sleep.

The patient had a strong family history of similar sleep-related events; his father and brother had been fully investigated and diagnosed with nocturnal epilepsy on the basis of video-EEG monitoring. His father had suffered frequent and troublesome nocturnal events, which started in early childhood, and which were diagnosed as night terrors and psychogenic attacks for many years. His grandmother also had a history of troublesome sleepwalking in her early life, which had settled spontaneously soon after the birth of her first child.

Standard investigations, including MRI and EEG (during sleep and wakefulness), were normal. Video-EEG monitoring captured several events consistent with frontal lobe seizures, characterized by sitting forward with dystonic posturing of the upper limbs and hypermotor bipedal automatisms of the legs. EEG during these episodes was significantly marred by movement artefact, but bifrontal rhythmic sharp and slow activity was clearly present during some of the attacks.

He commenced on carbamazepine, which reduced his seizure frequency, but the episodes still occurred during periods of sleep deprivation or stress. However, during his twenties, the episodes became gradually less frequent and eventually stopped without further changes to his medication regimen at 23 years. He remained seizure-free on carbamazepine monotherapy.

Biological basis

Etiology and pathogenesis

The etiology of sleep-related hypermotor (hyperkinetic) epilepsy may be genetic, genetic–structural, or acquired. In a majority of patients, the etiology is unknown. No specific clinical features distinguish etiologies.

Familial sleep-related hypermotor epilepsy is usually inherited in an autosomal dominant fashion (autosomal dominant sleep-related hypermotor epilepsy, ADSHE), with a penetrance of approximately 70%. A pathogenic gene variant is found in approximately 19% of ADSHE and in 7% of sporadic sleep-related hypermotor epilepsy. Genetic causes of ADSHE include pathogenic variants in GATOR1 complex genes (DEPDC5, less frequently NPRL2 or NPRL3), in acetylcholine receptor subunit genes (CHRNA4, less frequently CHRNB2 or CHRNA2), and in the sodium-activated potassium channel gene KCNT1. Individuals with GATOR complex pathogenic gene variants may have focal cortical dysplasias, with implications for epilepsy surgery. Individuals with KCNT1 pathogenic variants have a more severe form of sleep-related hypermotor epilepsy, with intellectual disability, psychosis, and sometimes regression, and higher penetrance in families. Rare families with autosomal recessive sleep-related hypermotor epilepsy are described, and pathogenic variants in PRIMA1 have been identified in one family.

nAChR gene mutations. Mutations in CHRNA4, CHRNB2, and CHRNA2 can cause ADSHE (70; 51; 01) and are estimated to account for 10% to 20% of families in some populations (48). Penetrance is estimated at 70% in these families. Functional studies of the nicotinic receptor mutations associated with ADSHE demonstrate that result is gain-of-function, sometimes with altered response to antiepileptic medications and acetylcholine (10; 23; 24; 69). The importance of cholinergic signaling in sleep-related hypermotor epilepsy has also been emphasized by the finding of homozygous mutation in the gene PRIMA1 (which encodes a protein that anchors acetylcholinesterase to the neuronal membrane) in a family with autosomal recessive sleep-related hypermotor epilepsy (22).

Nevertheless, the mechanism by which mutations in the nAChR subunit genes result in epilepsy is not clear. The nAChRs are important ligand-gated ion channels that are distributed widely throughout the central nervous system, although the function of these receptors is only partially understood. There is good evidence that they are involved in presynaptic modulation of neurotransmitter release in a number of systems, enhancing the release of norepinephrine, dopamine, GABA, serotonin, and acetylcholine (61). In addition, there may be direct nicotinic synaptic neurotransmission in the CNS (although there is relatively little evidence of this), and the nAChR is believed to play a role in the regulation of gene expression and neuronal pathfinding during development (61). Positron emission tomography (PET) studies have suggested that this developmental function may be important in ADSHE, possibly via influences on dopamine receptor expression (19) or through changes in regional nAChR density (55).

KCNT1 mutations. The discovery of missense mutations in the sodium-gated potassium channel gene KCNT1 in families with severe ADSHE (21), and a sporadic case with a de novo mutation, demonstrated that other genetic mechanisms can also cause ADSHE. Mutations in this gene appear to be associated with a fully penetrant, often more severe form of ADSHE associated with behavioral and psychiatric problems and intellectual disability, but with otherwise typical seizure semiology. Psychiatric features include aggression and psychosis; severe developmental regression is also observed (16). Intriguingly, de novo KCNT1 mutations have also been identified in the syndrome of epilepsy of infancy with migrating focal seizures (EIMFS), a severe epileptic encephalopathy associated with migrating focal seizures and profound developmental impairment (04). A family was comprised of four children with two sets of half-siblings, two half-siblings with ADSHE and two half-siblings with EIMFS inherited from their mildly affected mother with ADSHE (39). Functional studies of the mutations causing EIMFS are consistent with a gain of function resulting in hyperexcitability (04), though there is a single report of a child with EIMFS and a KCNT1 loss of function mutation with decreased membrane expression (18). KCNT1 mutations causing ADSHE show gain of function but less than that observed in EIMFS (38). The precise function of KCNT1 and how mutations in this gene result in these distinct epilepsy phenotypes is, however, poorly understood.

mTOR pathway gene mutations. In 2013, the gene underlying familial focal epilepsy with variable foci (FFEVF) was discovered to be DEPDC5 (67; 25; 17). FFEVF is characterized by autosomal dominant inheritance of focal epilepsies in which different family members have focal epilepsies emanating from different cortical regions (67). DEPDC5 mutations were identified in seven of the eight large families reported (82; 11; 09; 42; 17). When small families with two or more individuals with focal epilepsy were studied for DEPDC5 mutations, 12% (10 out of 82) had mutations. Some families only contained individuals with sleep-related hypermotor epilepsy and could, therefore, have been diagnosed with ADSHE. These families effectively represent a subset of FFEVF in which some families only express a sleep-related hypermotor epilepsy phenotype. Many of the DEPDC5 mutations produce truncation of the protein and consequent haploinsufficiency.

DEPDC5 is a subunit of the GATOR1 complex, which exhibits regulatory control over mammalian target of rapamycin (mTOR), a protein complex involved in regulation of cell proliferation, among other functions (05). The other two components of GATOR1 are NPRL2 and NPRL3. Mutations of the genes encoding these proteins (NPRL2 and NPRL3) have also been identified in a smaller fraction of families with FFEVF, with individuals having sleep-related hypermotor, temporal lobe seizures, or other focal epilepsies (60; 78). Rare ADSHE families have been identified with mutations of GATOR1 genes (17; 26; 60).

An ADSHE family was described with bottom of the sulcus focal cortical dysplasia in two individuals and nonlesional sleep-related hypermotor epilepsy in the remainder of the family who were well characterized (66). Exome sequencing identified a truncation mutation of DEPDC5 in this family, highlighting that this gene could cause lesional and nonlesional epilepsy in a family. This observation has subsequently been confirmed in other families with focal cortical dysplasia and GATOR1 mutations (06; 60; 78). The mechanism of action by which mutations in GATOR1 genes result in epilepsy may relate to small, radiologically unidentifiable, focal cortical dysplasias in those with nonlesional epilepsy. In those with overt focal cortical dysplasia, a second hit such as a mutation in a gene within the same pathway may result in a developmental lesion (63). That mutation may be restricted to the lesional region or germline in origin.

In addition to MTOR regulator genes, a mother-daughter pair, both with nonlesional sleep-related hypermotor epilepsy, were identified and found to both carry a possibly pathogenic variant in the MTOR gene itself (40). Further study is necessary to clarify whether MTOR mutations are a significant cause of ADSHE.

CRH mutations. Missense mutations in the promoter and coding regions of CRH, encoding corticotropin-releasing hormone, have also been implicated in ADSHE (13; 62). The phenotype in these cases appears to be relatively mild, with no reports of the intellectual or psychiatric comorbidities. The mechanism by which altered CRH expression or function leads to epilepsy remains unclear; however, animal studies have demonstrated a proconvulsive effect of corticotropin-releasing hormone in the developing brain (03).

ADSHE can be caused by mutations in different genes and likely arises through different etiologic mechanisms, including channelopathies and focal cortical dysplasia. Even within the same family, variable presentations can be seen, demonstrating that ADSHE exhibits both genetic and phenotypic heterogeneity. The term “phenotypic heterogeneity” refers to the phenomenon of a single genetic mutation producing a phenotype of widely differing severity; this variability is usual within families with ADSHE (65). “Genetic heterogeneity,” on the other hand, describes different mutations causing a similar phenotype and takes two forms: allelic heterogeneity, referring to different mutations at the same locus, and locus heterogeneity, referring to mutations at different loci. Both forms of genetic heterogeneity are seen in ADSHE.

CABP4. A large family with ADSHE was reported in which all affected individuals had a variant in CABP4, the gene encoding calcium-binding protein 4 (12). The significance of CABP4 in ADSHE is unclear at this time, as the familial variant in this report is also present 19 times in the Genome Aggregation Database, of individuals without severe childhood-onset disease.

Mutations in known genes still only account for approximately 20% to 30% of ADSHE cases; thus, the remainder must occur via other mechanisms. These include as yet unrecognized genes acting in a monogenic fashion, though some cases may occur as a result of complex or polygenic inheritance. Epigenetic phenomena may also play an important role in some families.

Differential diagnosis

The principal differential diagnosis of nocturnal frontal lobe epilepsy is benign sleep disorders, primarily the NREM arousal parasomnias (15). However, a number of sleep disorders can cause potential confusion with sleep-related hypermotor (hyperkinetic) epilepsy, including the following:

• NREM arousal parasomnias (sleepwalking, confusional arousals, sleep terrors)
• REM sleep behavior disorder
• Rhythmic movement disorder of sleep (jactatio capitis nocturna)
• Catathrenia (nocturnal groaning)
• Sleep starts
• Nocturnal panic attacks
• Psychogenic non-epileptic attacks
• Sleep-related breathing disorders

Despite the relatively long list of differential diagnoses, by far the biggest practical problem in clinical setting is the distinction of sleep-related hypermotor epilepsy from the NREM arousal parasomnias such as sleep terrors and somnambulism. A careful history, however, will usually be sufficient to distinguish these disorders (14). In the patient with paroxysmal nocturnal events, the most important historical features indicating sleep-related hypermotor epilepsy as opposed to benign parasomnias are the timing of events (in sleep-related hypermotor epilepsy this is often within 30 minutes of sleep onset, whereas parasomnias typically occur between 1 and 2 hours after sleep onset); the number of events per night (in sleep-related hypermotor epilepsy, there are often multiple events in a single night, whereas parasomnias rarely occur more than once or twice per night); the duration of events, which may be brief or prolonged in parasomnias, but in sleep-related hypermotor epilepsy are almost invariably brief (usually less than 1 minute); and the presence of an aura (very common in at least a proportion of seizures in individuals with sleep-related hypermotor epilepsy, but almost never a feature of parasomnias). Extensive wandering is rare (though occasional) in sleep-related hypermotor epilepsy but is common in parasomnias; conversely, lucid recall for events is common in at least a proportion of seizures in some patients with sleep-related hypermotor epilepsy but is very uncommon in parasomnias (although some vague recollection is not uncommon).

Importantly, few individual features are exclusive to either condition, and the diagnosis must be made by taking into account all pertinent aspects of the history. This can be problematic, even for clinicians with considerable experience with these disorders. The diagnostic process may be improved by use of the Frontal Lobe Epilepsy and Parasomnias (FLEP) scale. This is a brief, validated clinical questionnaire that has been shown to generate reliable diagnoses on the basis of the history in most cases in this setting (14).

Although the history is paramount in this setting, in some cases video-EEG monitoring is required to make a diagnosis. However, this is only practical when events are happening on a frequent basis. Moreover, events in sleep-related hypermotor epilepsy are often associated with normal or non-specific EEG features, and in some cases diagnosis may be difficult even if events are successfully recorded. The key to diagnosis is the stereotyped nature of the attacks, which can be identified on video-EEG studies.

Once sleep-related hypermotor epilepsy has been diagnosed, a careful family history is essential to detect ADSHE. As penetrance is 70%, the diagnosis may not be readily apparent, especially as there is great variation in disease severity between individuals in any given family. Many affected individuals may have only very mild events, and adults in a family may have had no events since childhood or adolescence. A superficially taken family history may often miss affected relatives who are not diagnosed as having epilepsy.

Diagnostic workup

The diagnostic workup in ADSHE is the same as for any patient with epilepsy. It is important to appreciate that the history of the events and family history are paramount in arriving at the correct diagnosis, and other investigations may be noncontributory in many cases.

Routine EEG in wakefulness is normal in up to 90% of individuals with ADSHE, but sleep EEG shows frontally dominant epileptiform discharges in up to 50% (47).

Video-EEG monitoring may be essential in some patients to make the diagnosis, but diagnostic uncertainty may occasionally remain even after monitoring. Ictal patterns include evolving sharp or spike-and-wave discharges, rhythmic slow activity, or diffuse background flattening over frontal areas. Postictal focal slowing may be seen. Intracranial EEG recordings (eg, stereo-EEG) have demonstrated that ictal discharges may start in various extrafrontal areas (insulo-opercular, temporal, and parietal cortices). The key to the diagnosis remains in reviewing the events and confirming the stereotyped semiology, especially in cases without clear electrographic correlate on the scalp EEG. Electrographically, seizures tend to occur during NREM sleep, with about 70% occurring in stage 1 or 2.

Neuroimaging is usually normal. Occasionally, a structural brain abnormality is found, most commonly focal cortical dysplasia but also, less commonly, an acquired structural pathology.

At present, there is a limited role for diagnostic genetic testing in sleep-related hypermotor epilepsy. The diagnosis is made on the clinical presentation and family history in ADSHE. Where a patient has no known family history and no lesion is found on MRI, mutational analysis may uncover a de novo mutation in some cases with significant genetic counselling implications (52; 21). Multi-gene panels and next-generation sequencing techniques are becoming increasingly popular and affordable modalities; however, the yield in cases of sleep-related hypermotor epilepsy may be low given the relatively low frequency of mutations in known genes. Once a genetic mutation is found, it carries considerable implications in terms of selection of medications, recognition of comorbidities, and genetic counseling.

Management

Seizures in sleep-related hypermotor (hyperkinetic) epilepsy are usually responsive to treatment with antiseizure medications, with carbamazepine being particularly effective (65; 47; 71; 54; 20). Both acetazolamide and lacosamide have been reported as effective in resistant cases of SHE/ADSHE (75; 31). A case series of 24 individuals with ADSHE treated with topiramate reported seizure freedom, or a 50% reduction of seizures, in almost all cases (87.5%) (46). Perampanel has been studied as an add-on agent.

An open-label trial of fenofibrate as add-on therapy in 11 adults with sleep-related hypermotor epilepsy, five of whom had ADSHE, found that seizure frequency decreased and quality of life was improved (58). In a single patient with a known alpha4 nicotinic acetylcholine receptor subunit gene mutation, nicotine (administered via patch) was found to result in a significant reduction in seizure frequency (80); however, nicotine has not been used in larger trials in ADSHE.

In cases with KCNT1 mutations, the KCNT1 gain of function shows dose-dependent reversibility with quinidine, a broad-spectrum potassium channel blocker (38). Although case reports describe some benefit of quinidine in terms of seizure reduction and mild developmental gains in children with EIMFS, a single case of KCNT1 focal epilepsy with regression did not derive any benefit (07; 37). A placebo-controlled randomized trial of quinidine for sleep-related hypermotor epilepsy with KCNT1 mutations also did not show a therapeutic benefit, and several patients developed prolonged PT intervals even at low quinidine doses (45).

Outcomes

Outcome is primarily a function of the underlying etiology. A study with 139 patients with sleep-related hypermotor epilepsy showed total remission in only 22.3% of the cohort (29). This included sporadic and familial cases. Any underlying brain disorder (any combination of intellectual disability, perinatal insult, pathologic neurologic examination, and brain structural abnormalities) and seizures in wakefulness were more frequent among the group with refractory seizures.

Intellect is normal in most cases but over half of sleep-related hypermotor epilepsy patients will have some degree of neuropsychological deficit on formal testing (30). Those with gene mutations have greater risk of intellectual disability (30); in particular, individuals with KCNT1 mutations typically have intellectual disability and severe psychiatric and behavioral comorbidities.

Epilepsy surgery may be effective in some children with focal cortical dysplasia. Seizure outcomes may be compromised by extensive epileptogenic zones.

References

01: Aridon P, Marini C, Di Resta C, et al. Increased sensitivity of the neuronal nicotinic receptor alpha 2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. Am J Hum Genet 2006;79(2):342-50. PMID 16826524
02: Bagnall RD, Crompton DE, Petrovski S, et al. Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy. Ann Neurol 2016;79(4):522-34. PMID 26704558
03: Baram TZ, Schultz L. ACTH does not control neonatal seizures induced by administration of exogenous corticotropin-releasing hormone. Epilepsia 1995;36(2):174-8. PMID 7821275
04: Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 2012;44(11):1255-9. PMID 23086397
05: Bar-Peled L, Chantranupong L, Cherniack AD, et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013;340(6136):1100-6. PMID 23723238
06: Baulac S, Ishida S, Marsan E, et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol 2015;77(4):675-83. PMID 25623524
07: Bearden D, Strong A, Ehnot J, DiGiovine M, Dlugos D, Goldberg EM. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 2014;76(3):457-61. PMID 25042079
08: Berger HJ, Berendsen-Versteeg TM, Joosten EM. Nocturnal paroxysmal dystonia. J Neurol Neurosurg Psychiatry 1987;50(5):647-8. PMID 3585397
09: Berkovic SF, Serratosa JM, Phillips HA, et al. Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12. Epilepsia 2004;45(9):1054-60. PMID 15329069
10: Bertrand D, Elmslie F, Hughes E, et al. The CHRNB2 mutation I312M is associated with epilepsy and distinct memory deficits. Neurobiol Dis 2005;20(3):799-804. PMID 15964197
11: Callenbach PM, van den Maagdenberg AM, Hottenga JJ, et al. Familial partial epilepsy with variable foci in a Dutch family: clinical characteristics and confirmation of linkage to chromosome 22q. Epilepsia 2003;44(10):1298-305. PMID 14510823
12: Chen ZH, Wang C, Zhuo MQ, et al. Exome sequencing identified a novel missense mutation c.464G>A (p.G155D) in Ca(2+)-binding protein 4 (CABP4) in a Chinese pedigree with autosomal dominant nocturnal frontal lobe epilepsy. Oncotarget 2017;8(45):78940-7. PMID 29108277
13: Combi R, Dalpra L, Ferini-Strambi L, Tenchini ML. Frontal lobe epilepsy and mutations of the corticotropin-releasing hormone gene. Ann Neurol 2005;58(6):899-904. PMID 16222669
14: Derry CP, Davey M, Johns M, et al. Distinguishing sleep disorders from seizures: diagnosing bumps in the night. Arch Neurol 2006b;63(5):705-9. PMID 16682539
15: Derry CP, Duncan JS, Berkovic SF. Paroxysmal motor disorders of sleep: the clinical spectrum and differentiation from epilepsy. Epilepsia 2006a;47(11):1775-91. PMID 17116016
16: Derry CP, Heron S, Phillips F, et al. Severe autosomal dominant nocturnal frontal lobe epilepsy associated with psychiatric disorders and intellectual disability. Epilepsia 2008;49(12):2125-9. PMID 18479385
17: Dibbens LM, De Vries B, Donatello S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013;45(5):546-51. PMID 23542697
18: Evely KM, Pryce KD, Bhattacharjee A. The Phe932Ile mutation in KCNT1 channels associated with severe epilepsy, delayed myelination and leukoencephalopathy produces a loss-of-function channel phenotype. Neuroscience 2017;351:65-70. PMID 28366665
19: Fedi M, Berkovic SF, Scheffer IE, et al. Reduced striatal D1 receptor binding in autosomal dominant nocturnal frontal lobe epilepsy. Neurology 2008;71(11):795-8. PMID 18685138
20: Gambardella A, Annesi G, De Fusco M, et al. A new locus for autosomal dominant nocturnal frontal lobe epilepsy maps to chromosome 1. Neurology 2000;55(10):1467-71. PMID 11094099
21: Heron SE, Smith KR, Bahlo M, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 2012;44(11):1188-90.** PMID 23086396
22: Hildebrand MS, Tankard R, Gazina EV, et al. PRIMA1 Mutation: a new cause of nocturnal frontal lobe epilepsy. Ann Clin Transl Neurol 2015;2(8):821-30. PMID 26339676
23: Hoda J, Gu W, Friedli M, et al. Human nocturnal frontal lobe epilepsy: pharmocogenomic profiles of pathogenic nicotinic acetylcholine receptor beta-subunit mutations outside the ion channel pore. Mol Pharmacol 2008;74:374-91. PMID 18456869
24: Hoda JC, Wanischeck M, Bertrand D, Steinlein OK. Pleiotropic functional effects of the first epilepsy-associated mutation in the human CHRNA2 gene. FEBS Lett 2009;583(10):1599-604. PMID 19383498
25: Klein KM, O’Brien TJ, Praveen K, et al. Familial focal epilepsy with variable foci mapped to chromosome 22q12: expansion of the phenotypic spectrum. Epilepsia 2012;53(8):e151-5. PMID 22780917
26: Korenke GC, Eggert M, Thiele H, Nurnberg P, Sander T, Steinlein OK. Nocturnal frontal lobe epilepsy caused by a mutation in the GATOR1 complex gene NPRL3. Epilepsia 2016;57(3):e60-3. PMID 26786403
27: Lee BI, Lesser RP, Pippenger CE, et al. Familial paroxysmal hypnogenic dystonia. Neurology 1985;35(9):1357-60. PMID 4022385
28: Lehkuniec E, Micheli F, De Arbelaiz R, Torres M, Paradiso G. Concurrent hypnogenic and reflex paroxysmal dystonia. Mov Disord 1988;3(4):290-4. PMID 3211175
29: Licchetta L, Bisulli F, Vignatelli L, et al. Sleep-related hypermotor epilepsy: long-term outcome in a large cohort. Neurology 2017;88(1):70-77. PMID 27881627
30: Licchetta L, Poda R, Vignatelli L, et al. Profile of neuropsychological impairment in sleep-related hypermotor epilepsy. Sleep Med 2018;48:8-15. PMID 29843024
31: Liguori C, Romigi A, Placidi F, Sarpa MG, Mercuri NB, Izzi F. Effective treatment of nocturnal frontal lobe epilepsy with lacosamide: a report of two cases. Sleep Med 2016;23:121-2. PMID 26922622
32: Lugaresi E, Cirignotta F. Hypnogenic paroxysmal dystonia: epileptic seizure or a new syndrome. Sleep 1981;4(2):129-38. PMID 7256073
33: Lugaresi E, Cirignotta F, Montagna P. Nocturnal paroxysmal dystonia. J Neurol Neurosurg Psychiatry 1986;49(4):375-80. PMID 2939199
34: Magnusson A, Stordal E, Brodtkorb E, Steinlein O. Schizophrenia, psychotic illness and other psychiatric symptoms in families with autosomal dominant nocturnal frontal lobe epilepsy caused by different mutations. Psychiatr Genet 2003;13(2):91-5. PMID 12782965
35: Maselli RA, Rosenberg RS, Spire JP. Episodic nocturnal wanderings in non-epileptic young patients. Sleep 1988;11(2):156-61. PMID 3381056
36: Meierkord H, Fish DR, Smith SJ, Scott CA, Shorvon SD, Marsden CD. Is nocturnal paroxysmal dystonia a form of frontal lobe epilepsy. Mov Disord 1992;7(1):38-42. PMID 1557065
37: Mikati MA, Jiang YH, Carboni M, et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol 2015;78(6):995-9. PMID 26369628
38: Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014;75(4):581-90. PMID 24591078
39: Moller RS, Heron SE, Larsen LH, et al. Mutations in KCNT1 cause a spectrum of focal epilepsies. Epilepsia 2015;56(9):e114-20. PMID 26122718
40: Moller RS, Weckhuysen S, Chipaux M, et al. Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy. Neurol Genet 2016;2(6):e118. PMID 27830187
41: Montagna P, Sforza E, Tinuper P, Cirignotta F, Lugaresi E. Paroxysmal arousals during sleep. Neurology 1990;40(7):1063-6. PMID 2356007
42: Morales-Corraliza J, Gomez-Garre P, Sanz R, Díaz-Otero F, Gutierrez-Delicado E, Serratosa JM. Familial partial epilepsy with variable foci: a new family with suggestion of linkage to chromosome 22q12. Epilepsia 2010;51(9):1910-4. PMID 20659149
43: Morris HH, 3rd, Dinner DS, Luders H, Wyllie E, Kramer R. Supplementary motor seizures: clinical and electroencephalographic findings. Neurology 1988;38(7):1075-82. PMID 3386826
44: Mostacci B, Bisulli F, Vignatelli L, et al. Incidence of sudden unexpected death in nocturnal frontal lobe epilepsy: a cohort study. Sleep Med 2015;16(2):232-6. PMID 25600783
45: Mullen SA, Carney PW, Roten A, et al. Precision therapy for epilepsy due to KCNT1 mutations: a randomized trial of oral quinidine. Neurology 2018;90(1):e67-e72. PMID 29196578
46: Oldani A, Manconi M, Zucconi M, Martinelli C, Ferini-Strambi L. Topiramate treatment for nocturnal frontal lobe epilepsy. Seizure 2006;15(8):649-52. PMID 16973383
47: Oldani A, Zucconi M, Asselta R, et al. Autosomal dominant nocturnal frontal lobe epilepsy. A video-polysomnographic and genetic appraisal of 40 patients and delineation of the epileptic syndrome. Brain 1998;121(Pt 2):205-23. PMID 9549500
48: Ottman R, Hirose S, Jain S, et al. Genetic testing in the epilepsies–report of the ILAE Genetics Commission. Epilepsia 2010;51(4):655-70. PMID 20100225
49: Pedley TA, Guilleminault C. Episodic nocturnal wanderings responsive to anticonvulsant drug therapy. Ann Neurol 1977;2(1):30-5. PMID 900905
50: Peled R, Lavie P. Paroxysmal awakenings from sleep associated with excessive daytime somnolence: a form of nocturnal epilepsy. Neurology 1986;36(1):95-8. PMID 3941791
51: Phillips HA, Favre I, Kirkpatrick M, et al. CHRNB2 is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy. Am J Hum Genet 2001;68(1):225-31. PMID 11104662
52: Phillips HA, Marini C, Scheffer IE, Sutherland GR, Mulley JC, Berkovic SF. A de novo mutation in sporadic nocturnal frontal lobe epilepsy. Ann Neurol 2000;48(2):264-7. PMID 10939581
53: Phillips HA, Scheffer IE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2. Nat Genet 1995;10(1):117-8. PMID 7647781
54: Picard F, Bertrand S, Steinlein OK, Bertrand D. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 1999;40(9):1198-209. PMID 10487182
55: Picard F, Bruel D, Servent D, et al. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain 2006;129(Pt 8):2047-60. PMID 16815873
56: Picard F, Pegna AJ, Arntsberg V, et al. Neuropsychological disturbances in frontal lobe epilepsy due to mutated nicotinic receptors. Epilepsy Behav 2009;14(2):354-9. PMID 19059498
57: Provini F, Plazzi G, Tinuper P, Vandi S, Lugaresi E, Montagna P. Nocturnal frontal lobe epilepsy. A clinical and polygraphic overview of 100 consecutive cases. Brain 1999;122(Pt 6):1017-31. PMID 10356056
58: Puligheddu M, Melis M, Pillolla G, et al. Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy. Epilepsia 2017;58(10):1762-70. PMID 28766701
59: Rasmussen T. Characteristics of a pure culture of frontal lobe epilepsy. Epilepsia 1983;24(4):482-93. PMID 6873005
60: Ricos MG, Hodgson BL, Pippucci T, et al. Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann Neurol 2016;79(1):120-31. PMID 26505888
61: Role LW, Berg DK. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 1996;16(6):1077-85. PMID 8663984
62: Sansoni V, Forcella M, Mozzi A, et al. Functional characterization of a CRH missense mutation in an ADNFLE family. PLoS One 2013;8(4):e61306. PMID 23593457
63: Scerri T, Riseley JR, Gillies G, et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann Clin Transl Neurol 2015;2(5):575-80. PMID 26000329
64: Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet 1994;343(8896):515-7. PMID 7906762
65: Scheffer IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 1995;118(Pt 1):61-73.** PMID 7895015
66: Scheffer IE, Heron SE, Regan BM, et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 2014;75(5):782-7. PMID 24585383
67: Scheffer IE, Phillips HA, O'Brien CE, et al. Familial partial epilepsy with variable foci: a new partial epilepsy syndrome with suggestion of linkage to chromosome 2. Ann Neurol 1998;44(6):890-9. PMID 9851433
68: Spencer SS, Spencer DD, Williamson PD, Mattson RH. Sexual automatisms in complex partial seizures. Neurology 1983;33(5):527-33. PMID 6682492
69: Steinlein OK, Hoda JC, Bertrand S, Bertrand D. Mutations in familial nocturnal frontal lobe epilepsy might be associated with distinct neurological phenotypes. Seizure 2012;21(2):118-23. PMID 22036597
70: Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11(2):201-3. PMID 7550350
71: Thomas P, Picard F, Hirsch E, Chatel M, Marescaux C. [Autosomal dominant nocturnal frontal lobe epilepsy]. Rev Neurol (Paris) 1998;154(3):228-35. PMID 9773047
72: Tinuper P, Bisulli F, Cross JH, et al. Definition and diagnostic criteria of sleep-related hypermotor epilepsy. Neurology 2016;86(19):1834-42.** PMID 27164717
73: Tinuper P, Cerullo A, Cirignotta F, Cortelli P, Lugaresi E, Montagna P. Nocturnal paroxysmal dystonia with short-lasting attacks: three cases with evidence for an epileptic frontal lobe origin of seizures. Epilepsia 1990;31(5):549-56. PMID 2401246
74: Tinuper P, Lugaresi E. The concept of paroxysmal nocturnal dystonia. In: Bazil CW, Malow BA, Sammaritano MR, editors. Sleep and Epilepsy: the Clinical Spectrum. Amsterdam: Elsevier Science, 2002:277-82.
75: Varadkar S, Duncan JS, Cross JH. Acetazolamide and autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia 2003;44(7):986-7. PMID 12823586
76: Vignatelli L, Bisulli F, Giovanni G, et al. Prevalence of nocturnal frontal lobe epilepsy in the adult population of Bologna and Modena, Emilia-Romagna region, Italy. Sleep 2015;38(3):479-85. PMID 25406112
77: Waterman K, Purves SJ, Kosaka B, Strauss E, Wada JA. An epileptic syndrome caused by mesial frontal lobe seizure foci. Neurology 1987;37(4):577-82. PMID 3104818
78: Weckhuysen S, Marsan E, Lambrecq V, et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia 2016;57(6):994-1003. PMID 27173016
79: Williamson PD, Spencer DD, Spencer SS, Novelly RA, Mattson RH. Complex partial seizures of frontal lobe origin. Ann Neurol 1985;18(4):497-504. PMID 4073842
80: Willoughby JO, Pope KJ, Eaton V. Nicotine as an antiepileptic agent in ADNFLE: an N-of-one study. Epilepsia 2003;44(9):1238-40. PMID 12919397
81: Wood AG, Saling MM, Fedi M, et al. Neuropsychological function in patients with a single gene mutation associated with autosomal dominant nocturnal frontal lobe epilepsy. Epilepsy Behav 2010;17(4):531-5. PMID 20189461
82: Xiong L, Labuda M, Li DS, et al. Mapping of a gene determining familial partial epilepsy with variable foci to chromosome 22q11-q12. Am J Hum Genet 1999;65(6):1698-710. PMID 10577924

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Isaac Molinero MD

Dr. Molinero of the Michael R Boh Center for Child Development has no relevant financial relationships to disclose.
See Profile

Editor

Solomon L Moshé MD

Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Kenneth A Myers MD PhD
Christopher P Derry MBBS PhD
Ingrid E Scheffer MBBS PhD
Jerome Engel Jr MD PhD

Patient Profile

Age range of presentation: The range of seizure onset is from 1 to 52 years; some individuals present with mild events.
Sex preponderance: Male=female, autosomal dominant inheritance
Heredity: Heredity may be a factor

Heredity typical

Autosomal dominant
Population groups selectively affected: No formal population studies have been undertaken to address this issue, and ADSHE is relatively uncommon. From reports in the literature, there are no definite population groups that appear to be preferentially affected by ADSHE, and the condition has been reported in a number of ethnic groups. A relatively large number of cases have been reported from Italy, although whether this reflects higher rates of occurrence or detection of the disorder is unclear.
Occupation groups selectively affected: None

ICD & OMIM codes

OMIM: Epilepsy, familial focal, with variable foci (FFEVF): #604364

Epilepsy, nocturnal frontal lobe, type 1: #600513

Epilepsy, nocturnal frontal lobe, type 2: %603204

Epilepsy, nocturnal frontal lobe, type 3: #605375

Epilepsy, nocturnal frontal lobe, type 4: #610353

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Sleep hyperkinetic (hypermotor) epilepsy

Associated Disorders

Familial focal epilepsy with variable foci
Nocturnal frontal lobe epilepsy
Sleep-related hypermotor epilepsy

Differential Diagnosis

NREM arousal parasomnias (sleepwalking, confusional arousals, sleep terrors)
REM behavior disorder
Rhythmic movement disorder of sleep (jactatio capitis nocturna)
Catathrenia (nocturnal groaning)
Sleep starts
- Nocturnal panic attacks
- Psychogenic non-epileptic attacks
- Sleep-related breathing disorders

Also Relevant

Carbamazepine
Epilepsy
Familial focal epilepsy
Frontal lobe seizures
Pharmacological treatment of epilepsy in adolescents and adults

Clinical Categories

Epilepsy & Seizures

Patient Handouts

Web References

Testing

Autosomal Dominant Nocturnal Frontal Lobe Epilepsy

Sleep hyperkinetic (hypermotor) epilepsy …

Sleep hyperkinetic (hypermotor) epilepsy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Sleep hyperkinetic (hypermotor) epilepsy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

This is an article preview.
Start a Free Account
to access the full version.